Perspectives on Use of Oral and Vaginal Antiretrovirals for HIV Prevention: the VOICE-C Qualitative Study in Johannesburg, South Africa

The VOICE trial of tenofovir-based vaginal gel and pills was unable to demonstrate efficacy for HIV prevention because of low adherence to study regimens. This study, published in a September 2014 supplement to the Journal of the International AIDS Society, explores views of and experiences with the use of antiretrovirals for HIV prevention among VOICE participants, their male partners, and community members and examines the implications for adherence.

Length: 
7 pages
Year: 
2014
Organization: 
RTI International, Center for AIDS Prevention Studies at the University of California at San Francisco, Wits Reproductive Health and HIV Institute
Languages: 
English
Author(s): 
van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET, The VOICE-C Study Team